Mechanism of action of oritavancin and related glycopeptide antibiotics. - Wikidata - wikimedia - TriplyDB

Mechanism of action of oritavancin and related glycopeptide antibiotics.

Mechanism of action of oritavancin and related glycopeptide antibiotics.

http://www.wikidata.org/entity/Q35066202

about

Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications Profile of oritavancin and its potential in the treatment of acute bacterial skin structure infections Resistance to antibiotics targeted to the bacterial cell wall Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey Exploring innate glycopeptide resistance mechanisms in Staphylococcus aureus Vancomycin analogs: Seeking improved binding of d-Ala-d-Ala and d-Ala-d-Lac peptides by side-chain and backbone modifications.Host-guest chemistry of the peptidoglycan Total synthesis of [Ψ[C(═NH)NH]Tpg(4)]vancomycin and its (4-chlorobiphenyl)methyl derivative: impact of peripheral modifications on vancomycin analogues redesigned for dual D-Ala-D-Ala and D-Ala-D-Lac binding.Synthesis and evaluation of selected key methyl ether derivatives of vancomycin aglycon.Investigational antimicrobial agents of 2013.Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages.Probing Membrane Insertion Activity of Antimicrobial Polymers via Coarse-grain Molecular Dynamics Current and novel antibiotics against resistant Gram-positive bacteria Progress in the discovery of treatments for C. difficile infection: A clinical and medicinal chemistry review.Total syntheses and initial evaluation of [Ψ[C(═S)NH]Tpg⁴]vancomycin, [Ψ[C(═NH)NH]Tpg⁴]vancomycin, [Ψ[CH₂NH]Tpg⁴]vancomycin, and their (4-chlorobiphenyl)methyl derivatives: synergistic binding pocket and peripheral modifications for the glycopeptide Oritavancin and tigecycline: investigational antimicrobials for multidrug-resistant bacteria.Enterococcus faecalis resistant to linezolid: case series and review of the literature.Redesign of glycopeptide antibiotics: back to the future Oritavancin: a new avenue for resistant Gram-positive bacteria.The antimicrobial armamentarium: evaluating current and future treatment options.Antibiotic resistance in Staphylococcus aureus and its relevance in therapy.Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections Oritavancin--an investigational glycopeptide antibiotic.Oritavancin exhibits dual mode of action to inhibit cell-wall biosynthesis in Staphylococcus aureus Modulation of hexa-acyl pyrophosphate lipid A population under Escherichia coli phosphate (Pho) regulon activation Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens.Molecular epidemiology of clinically significant antibiotic resistance genes.Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-pheno Oritavancin: a potential weapon in the battle against serious Gram-positive pathogens.Emergence and management of drug-resistant enterococcal infections.Vancomycin and oritavancin have different modes of action in Enterococcus faecium Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia.Surface mediated cooperative interactions of drugs enhance mechanical forces for antibiotic action.A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.Emerging drugs for complicated skin and skin-structure infections.Probing the biology of natural products: molecular editing by diverted total synthesis.Peptidoglycan biosynthesis machinery: a rich source of drug targets.Update on carbohydrate-containing antibacterial agents.

P2860

Q24556635-016F890A-F901-48F7-9BA0-54DAF538E5DC Q24646677-E9F75B52-D4F2-4C62-9420-42FA0F93C327 Q26799701-42C3DF61-8079-4740-9CCC-CF1FE2208BBC Q26859841-FA7182BB-770E-4333-B5AE-2F58232ED53D Q28235095-78CE8D61-E717-4B88-BF53-42CC8E876C04 Q33762805-26255E8D-BC91-4303-907A-50217392E306 Q33944429-63F8EC2A-1CA9-4CD4-91A5-C1966296AC84 Q34013593-2CA93E4F-F0C7-4DA3-88F3-EBB7C8A872C7 Q34282738-E811C189-3466-446F-9844-BCEB09C9CC94 Q34308628-84265F69-D39A-401F-93E9-159341365841 Q34375204-64AE31F9-CE38-4901-9887-23EFBFF6FF2C Q34509728-97403B68-F037-4047-AE6C-144F36DE6F47 Q34872972-EDEF94AE-5CE6-42C7-BB1D-DAE165309420 Q35026521-E1FCD82A-C517-4E04-BDF9-A7425C27FF5F Q35044119-DD3E2240-316E-49F3-A33E-B4F4537E0554 Q35224649-E6BC095D-7AAD-4B54-A162-6B099D724861 Q35637071-F9241BA4-3231-4299-B42C-056596C560ED Q35906331-6B5A236D-45C7-484F-9EE8-26101786156A Q35973511-E73BFAFC-F5B0-4DBA-A892-CBAB9A6BA674 Q36162339-D9CF6806-D1D2-42A8-A343-3DDEC25B452B Q36264494-D09A488C-9D6C-4197-8C51-16B9BFE0C5AA Q36283731-E18BA849-3C94-4B50-84B0-52C3631DD780 Q36393640-AE0CBA30-3C36-43EF-A5BD-75DFD9BDE74C Q36426011-527BC549-D1CC-4D3E-B874-9A3B3588D0B2 Q36512904-60BD8C5F-D7F1-47D8-A4BC-4FFC979CCCEC Q36804404-201B952F-E46C-4FAA-ABC0-E500DAF239B5 Q36870766-5ABA96F0-3C79-48F3-8D6E-8F71434DDC48 Q37071199-862B585E-7E3B-4EA4-AD8B-556F30054773 Q37098582-0C258E6E-96B0-4C37-B036-C838D246026F Q37144809-8B4F21CD-485C-4CBE-B530-36689A20BBF7 Q37174100-1B3D0D41-D9ED-4471-892E-CE89DDE974F2 Q37291346-F1E7E690-60E4-4270-9C09-255ACB35CCCF Q37356329-27BC0083-4343-48A2-B8C2-5C06E35B8394 Q37392932-60D05C38-28DF-4E8B-AE6E-FF7E18996DB2 Q37623139-84951FE2-D7B2-419F-A42B-8DEB704F79F5 Q37661510-7EE0ABCF-557E-4C7C-B84A-E62BAD4094E2 Q37765900-D7068AC9-CD37-4987-A5EC-9234E021B092 Q37809500-F7BFEE7A-CBD5-4CC6-BAC3-AD1C0A6BACF0 Q37810971-F7ADAEAF-B34C-4B81-8785-AE8BA9801275 Q38089193-FFE7D771-3827-46DE-ACE9-8F74AEB46E45

P2860

Mechanism of action of oritavancin and related glycopeptide antibiotics.

http://www.wikidata.org/entity/Q35066202

description

2003 nî lūn-bûn

@nan

2003 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Mechanism of action of oritavancin and related glycopeptide antibiotics.

@ast

Mechanism of action of oritavancin and related glycopeptide antibiotics.

@en

type

label

Mechanism of action of oritavancin and related glycopeptide antibiotics.

@ast

Mechanism of action of oritavancin and related glycopeptide antibiotics.

@en

prefLabel

Mechanism of action of oritavancin and related glycopeptide antibiotics.

@ast

Mechanism of action of oritavancin and related glycopeptide antibiotics.

@en

P1433

Q35066202-D877A672-74DF-4E1F-B49F-DB6A8DC590B2

P1476

Q35066202-FBE7F47E-9ECA-446C-BC94-14C9B415D0B1

P2093

Q35066202-57080D27-255E-4187-ABC8-FBB5585EE01D

Q35066202-F768D789-EBDB-4F5D-89A4-DBB8644776DE

P2860

Q35066202-020899AD-60E3-41E5-B93E-690F2782802F

Q35066202-046613F4-DEFA-4473-B185-2FE06F800CC1

Q35066202-0DD277BC-59EF-4DB2-BB1F-B2079E80B5ED

Q35066202-10F8C7E8-9C45-4A7A-AF77-DD3BA1791A59

Q35066202-14EC8929-287F-40FE-A71D-ADCC14FFD1AB

Q35066202-15AAB58A-E610-48F2-9669-4B520729F261

Q35066202-173673A4-EB65-432A-8911-DB5CED0EC1C4

Q35066202-18A4B0FE-8D6E-4FD6-A60C-8660DE1231DE

Q35066202-18FDDE82-E790-411E-9CBF-5DC60D24EC7E

Q35066202-1D12FB6C-B569-45E0-98D7-1379629FDF0C

P304

Q35066202-19E77217-EB9A-4331-88D4-31381BDB2599

P31

Q35066202-C52E231D-EB2F-4E5A-AFA5-82046817C09E

P356

Q35066202-AFCC8EBD-CC10-4558-B69A-37CE437C5532

P433

Q35066202-0D23CDBC-ACE5-42F4-85B1-7867AFF63BDE

P478

Q35066202-9254CB87-CA91-4DDB-89F7-2CA6675B6BBB

P577

Q35066202-4EB75D7C-6D39-4F43-B2F0-79D13FB549C3

P5875

Q35066202-1C9F1523-7E17-4C39-A654-2CBBCA6ADF05

P698

Q35066202-0009DD5E-4687-495E-B383-EBFFFEC3A950

P921

Q35066202-F57FCB8A-2D10-4BF7-9D84-E091DF745A4C

P356

J.1574-6976.2003.TB00628.X

P1433

FEMS Microbiology Reviews

P1476

Mechanism of action of oritavancin and related glycopeptide antibiotics.

@en

P2093

Norris E Allen

http://www.w3.org/2001/XMLSchema#string

Thalia I Nicas

http://www.w3.org/2001/XMLSchema#string

P2860

On the mechanism of action of vancomycin: inhibition of peptidoglycan synthesis in Gaffkya homari

On the attribution and additivity of binding energies

Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus

Vancomycin binding to low-affinity ligands: delineating a minimum set of interactions necessary for high-affinity binding

Conformation of A82846B, a glycopeptide antibiotic, complexed with its cell wall fragment: an asymmetric homodimer determined using NMR spectroscopy

Analysis of genes encoding D-alanine-D-alanine ligase-related enzymes in Enterococcus casseliflavus and Enterococcus flavescens

Contribution of VanY D,D-carboxypeptidase to glycopeptide resistance in Enterococcus faecalis by hydrolysis of peptidoglycan precursors.

Utilization of a depsipeptide substrate for trapping acyl-enzyme intermediates of penicillin-sensitive D-alanine carboxypeptidases.

In vitro activities of LY333328 and comparative agents against nosocomial gram-positive pathogens collected in a 1997 global surveillance study.

Activity of oritavancin (LY333328), an investigational glycopeptide, compared to that of vancomycin against multidrug-resistant Streptococcus pneumoniae in an in vitro pharmacodynamic model.

P304

511-532

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1574-6976.2003.TB00628.X

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P577

2003-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8221954

http://www.w3.org/2001/XMLSchema#string

P698

12586393

http://www.w3.org/2001/XMLSchema#string

P921